Cargando…
The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance
With the emergence of sodium-glucose cotransporter 2 inhibitors (SGLT2i), the treatment of type 2 diabetes mellitus (T2DM) has achieved a new milestone, of which the insulin-independent mechanism could produce weight loss, improve insulin resistance (IR) and exert other protective effects. Besides t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938665/ https://www.ncbi.nlm.nih.gov/pubmed/36820270 http://dx.doi.org/10.2147/DMSO.S399367 |
_version_ | 1784890681517408256 |
---|---|
author | Dong, Meiyuan Chen, Huiling Wen, Song Yuan, Yue Yang, Liling Li, Yanyan Yuan, Xinlu Xu, Dongxiang Zhou, Ligang |
author_facet | Dong, Meiyuan Chen, Huiling Wen, Song Yuan, Yue Yang, Liling Li, Yanyan Yuan, Xinlu Xu, Dongxiang Zhou, Ligang |
author_sort | Dong, Meiyuan |
collection | PubMed |
description | With the emergence of sodium-glucose cotransporter 2 inhibitors (SGLT2i), the treatment of type 2 diabetes mellitus (T2DM) has achieved a new milestone, of which the insulin-independent mechanism could produce weight loss, improve insulin resistance (IR) and exert other protective effects. Besides the well-acknowledged biochemical processes, the dysregulated balance between sympathetic and parasympathetic activity may play a significant role in IR and obesity. Weight loss caused by SGLT-2i could be achieved via activating the liver–brain–adipose neural axis in adipocytes. We previously demonstrated that SGLT-2 are widely expressed in central nervous system (CNS) tissues, and SGLT-2i could inhibit central areas associated with autonomic control through unidentified pathways, indicating that the role of the central sympathetic inhibition of SGLT-2i on blood pressure and weight loss. However, the exact pathway of SGLT2i related to these effects and to what extent it depends on the neural system are not fully understood. The evidence of how SGLT-2i interacts with the nervous system is worth exploring. Therefore, in this review, we will illustrate the potential neurological processes by which SGLT2i improves IR in skeletal muscle, liver, adipose tissue, and other insulin-target organs via the CNS and sympathetic nervous system/parasympathetic nervous system (SNS/PNS). |
format | Online Article Text |
id | pubmed-9938665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-99386652023-02-19 The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance Dong, Meiyuan Chen, Huiling Wen, Song Yuan, Yue Yang, Liling Li, Yanyan Yuan, Xinlu Xu, Dongxiang Zhou, Ligang Diabetes Metab Syndr Obes Review With the emergence of sodium-glucose cotransporter 2 inhibitors (SGLT2i), the treatment of type 2 diabetes mellitus (T2DM) has achieved a new milestone, of which the insulin-independent mechanism could produce weight loss, improve insulin resistance (IR) and exert other protective effects. Besides the well-acknowledged biochemical processes, the dysregulated balance between sympathetic and parasympathetic activity may play a significant role in IR and obesity. Weight loss caused by SGLT-2i could be achieved via activating the liver–brain–adipose neural axis in adipocytes. We previously demonstrated that SGLT-2 are widely expressed in central nervous system (CNS) tissues, and SGLT-2i could inhibit central areas associated with autonomic control through unidentified pathways, indicating that the role of the central sympathetic inhibition of SGLT-2i on blood pressure and weight loss. However, the exact pathway of SGLT2i related to these effects and to what extent it depends on the neural system are not fully understood. The evidence of how SGLT-2i interacts with the nervous system is worth exploring. Therefore, in this review, we will illustrate the potential neurological processes by which SGLT2i improves IR in skeletal muscle, liver, adipose tissue, and other insulin-target organs via the CNS and sympathetic nervous system/parasympathetic nervous system (SNS/PNS). Dove 2023-02-14 /pmc/articles/PMC9938665/ /pubmed/36820270 http://dx.doi.org/10.2147/DMSO.S399367 Text en © 2023 Dong et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Dong, Meiyuan Chen, Huiling Wen, Song Yuan, Yue Yang, Liling Li, Yanyan Yuan, Xinlu Xu, Dongxiang Zhou, Ligang The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance |
title | The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance |
title_full | The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance |
title_fullStr | The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance |
title_full_unstemmed | The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance |
title_short | The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance |
title_sort | neuronal and non-neuronal pathways of sodium-glucose cotransporter-2 inhibitor on body weight-loss and insulin resistance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938665/ https://www.ncbi.nlm.nih.gov/pubmed/36820270 http://dx.doi.org/10.2147/DMSO.S399367 |
work_keys_str_mv | AT dongmeiyuan theneuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT chenhuiling theneuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT wensong theneuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT yuanyue theneuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT yangliling theneuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT liyanyan theneuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT yuanxinlu theneuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT xudongxiang theneuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT zhouligang theneuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT dongmeiyuan neuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT chenhuiling neuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT wensong neuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT yuanyue neuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT yangliling neuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT liyanyan neuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT yuanxinlu neuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT xudongxiang neuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance AT zhouligang neuronalandnonneuronalpathwaysofsodiumglucosecotransporter2inhibitoronbodyweightlossandinsulinresistance |